BWA
LGND icon

Basecamp Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Basecamp Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Hold
41
– – ﹤0.01% 946
2026
Q1 		$8.19K Hold
41
– – ﹤0.01% 1073
2025
Q4 		$7.75K Buy
+41
New +$7.88K ﹤0.01% 1044

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's LGND Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 41 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Basecamp Wealth Advisors first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Basecamp Wealth Advisors held 41 shares of Ligand Pharmaceuticals worth $13K as of Q2 2026.
  • Basecamp Wealth Advisors left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #946 holding.
  • Basecamp Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.